Patients undergoing cardiac surgery with moderate hypothermic cardiopulmonary bypass (CPB) were allocated randomly to receive either saline (control group, nϭ29) or a high-dose regimen of aprotinin (aprotinin group, nϭ28). In both groups, CPB was associated with similar and transient increases in effective renal plasma flow (ϩ54% in controls and ϩ48% in aprotinintreated patients) and in fractional excretion of sodium and potassium, but glomerular filtration rate remained unchanged. Plasma and urinary ratios of 6-keto-PGF 1α to thromboxane B 2 (TxB 2 ) increased significantly, indicating systemic and renal release of vasodilatory prostaglandins. Osmolar clearance correlated with urinary excretion of cyclic GMP (rϭ0.79 and 0.86 in the control and aprotinin groups, respectively) and 6-keto-PGF 1α (rϭ0.63 and 0.69 in the control and aprotinin groups, respectively). Compared with preoperative values, plasma atrial natriuretic peptide increased after weaning from CPB (ϩ71% and ϩ93% in the control and aprotinin groups, respectively). Aprotinin had no apparent adverse effect on renal function and it did not alter mechanisms involving prostanoids and atrial natriuretic peptide during cardiac surgery.
Aprotinin, a non-specific serine protease inhibitor extracted kallikrein-kinin system in the kidney and promote diuresis from bovine lung or porcine gut, can reduce bleeding and renal vasodilatation. and blood transfusion requirements in patients undergoing
We designed a randomized double-blind study to assess cardiac operations, liver transplantation and orthopaedic the effects of aprotinin on renal haemodynamics and funcsurgery. [1] [2] [3] The use of aprotinin has become widespread tion in patients undergoing cardiac surgery. In addition, we and is not limited to patients at increased risk of bleeding questioned if release of vasoconstrictor and vasodilatory or those undergoing complex surgical procedures. 4 prostanoids (thromboxane A 2 (TxA 2 ) and prostacyclin) and However, concerns have been raised regarding its possible plasma ANP and cyclic GMP (cGMP), its second messenger, effects on renal function: in pigs, a large dose of aprotinin were influenced by aprotinin pretreatment. caused a reduction in renal blood flow during acute stress 5 and a multicentre, randomized, controlled study 6 reported Patients and methods more frequent increases in serum creatinine (Ͼ0.5 mg dl -1 )
After obtaining Institutional Ethics Committee approval in patients given aprotinin compared with placebo (30% vs and informed consent, we studied 60 patients undergoing 8%, respectively). Aprotinin is a small molecule (6512 Da) elective coronary artery bypass graft surgery, aortic valve and is freely filtered by the glomeruli and nearly completely replacement and mitral valve replacement or repair. We absorbed. Some suggest that the breakdown capacities of excluded those with diabetes or creatinine clearance values the convoluted tubules could be overwhelmed, allowing less than 30 ml min -1 . Patients in whom postoperative nephrotoxic effects. 7 In addition, aprotinin inhibits kallikrbleeding needed surgical haemostasis were also excluded. ein, the key enzyme in the kinin-generating pathway, which The patient's usual cardiac medications were administered triggers the release of potent vasodilatory mediators, such up to the morning of surgery. Peripheral venous, radial as prostacyclin and nitric oxide, from endothelial and renal arterial and central venous catheters were inserted for tubular cells. 8 9 In contrast, aprotinin delays degradation of atrial natriuretic peptide (ANP), 10 and greater plasma †This article is accompanied by Editorial II. fluid and drug administration in addition to haemodynamic glandular kallikrein which cleaves 0.05 mmol of substrate per minute. Intra-and inter-assay coefficients of variation measurements. Before operation, crystalloid 10 ml kg -1 was infused over 20 min. General anaesthesia was standardized were 4.2% and 7.1%, respectively. using fentanyl 40-60 µg kg -1 and midazolam 0.03-
Measurements and calculations
0.06 mg kg -1 followed by pancuronium 0.10 mg kg -1 h -1 for neuromuscular block (0.15 mg kg -1 at induction and Mean arterial pressure, heart rate and right atrial pressure were recorded. Glomerular filtration rate was assumed to 0.05 mg kg -1 during bypass). Mechanical ventilation was adjusted to obtain normocapnia and normoxia.
equal creatinine or inulin clearances (C IN , C creat ) and effective renal plasma flow was estimated as PAH clearance (C PAH ). Before cannulation of the aorta and right atrium, heparin sodium 300 u kg -1 was administered; additional heparin was Other tests of renal function included osmolar clearance (C Osm ), water clearance (C H 2 O ) and fractional sodium and given if the kaolin-activated clotting time (Hemochron 401, International Technidyne Corporation, Edison, NJ, USA) was potassium excretion. Blood and urinary samples were obtained at the following times: (1) baseline measurement, less than 550 s. Non-pulsatile cardiopulmonary bypass (CPB) was started with a membrane oxygenator (Cobe Laboratories 30 min before induction of anaesthesia (preop.), (2) before the start of bypass (pre-bypass), (3) before the second cardioInc., Lakewood, CO, USA) primed with crystalloid 2 litre; body temperature was decreased to achieve moderate hypo-plegia (bypass), (4) after administration of protamine (postbypass) and (5) on day 5 after operation. During operation, thermia (26-30°C) with α-stat regulation for pH management. After aortic clamping, myocardial protection was urine was collected over 30 min and arterial blood was obtained in the middle of each sampling period. Before and provided with St Thomas's solution 600-900 ml infused through the aortic root and repeated at 25-30-min intervals. after operation, urine was collected over 12 h and mean blood concentrations (for creatinine and electrolytes) at the During CPB, mean arterial pressure was maintained at 55-70 mm Hg using sodium nitroprusside, phenylephrine, or beginning and end of the clearance period were calculated.
Arterial blood was collected into cold tubes containing indoboth. Pump flow was maintained at greater than 2 and 2.4 litre min -1 m -2 during hypothermia and rewarming, respect-methacin and heparin (for prostaglandin assay) or dipotassium ethylenediamino-tetraacetic acid and aprotinin (for ively. After completion of the distal vascular anastomosis or valve surgery, patients were weaned from CPB when rectal ANP and cGMP assay) and was centrifuged immediately at 4°C. C IN and C PAH were measured only during operation. temperature was at least 35.5°C.
Fluids and vasoactive and inotropic agents were given to Urinary and plasma inulin and PAH concentrations were assayed spectrophotometrically. Serum and urinary sodium optimize haemodynamic conditions; packed red blood cells were given if blood haemoglobin concentration was less than and creatinine were measured with a standard flame emission photometer. All clearance values were corrected for a stand-9 g dl -1 .
ard body surface area of 1.73 m 2 .
Study procedure
Plasma concentrations of ANP and its second messenger cGMP, in addition to plasma and urinary concentrations of Patients were allocated randomly to one of two treatment groups in a double-blind manner. Each patient received a the stable metabolites of TxA 2 (thromboxane B 2 (TxB 2 )) and prostacyclin (6-keto-PGF 1α ) were determined before anaessimilar volume of saline or aprotinin. In the aprotinin group, each patient received 2 million kallikrein inhibitory units thesia and during operation (pre-op., pre-bypass, bypass and post-bypass). Plasma ANP was extracted from a 2-ml plasma (mkiu) over 30 min, 1 mkiu in the CPB priming volume and 0.5 mkiu h -1 i.v. from the start of surgery until skin closure. aliquot on a C-18 octadecylsilane cartridge (Sep-Pak, Waters
Associates, Milfford, MA, USA) and measured by a specific The mean dose was 4.1 mkiu/patient or approximately 50 000 kiu kg -1 .
radioimmunoassay; intra-and inter-assay variations were 3.9% and 13.7%, respectively. cGMP was measured after Before anaesthesia, priming doses of inulin 30 mg kg -1 (10% Inulin; Laevosan Gesellschaft mbH, Linz, Austria) and extraction by ethanol using a commercial kit (Amersham, UK); intra-and inter-assay variations were 4.5% and 10%, p-paraimmunohippurate 8 mg kg -1 (PAH, Merck, Sharp and Dohme, NJ, USA) were given i.v. followed by a continuous respectively. TxB 2 and 6-keto-PGF 1α concentrations were measured in infusion of both drugs at 0.2 and 0.15 mg kg -1 min -1 , respectively, up to the end of surgery. An equilibration period of 100-µl aliquots of plasma or urine by radioimmunoassay without extraction (Amersham, UK). The lower limit of sens-60 min was allowed before baseline measurements. Diuretics, mannitol or dopamine were not given during the study.
itivity was 30 pg ml -1 for both measurements. Excretion of urinary prostanoid metabolites was expressed as pg g creatiKallikrein concentrations were measured in urinary samples before and after bypass using the method of nine -1 .
Plasma concentrations of ANP, cGMP and prostanoids Amundsen and colleagues. 11 This assay measured urinary activity against the chromogenic substrate S-2266 were corrected for the haemodiluting effects of CPB according to the change in packed cell volume. (H-D-Val-Leu-Arg-pNA, AB Kabi Diagnostica, Stockholm, Sweden) for which urine kallikrein is highly specific. Results Intra-and postoperative i.v. fluid requirements (packed red blood cells, fresh frozen plasma, crystalloid and colloid are expressed as nkat litre -1 , where 1 nkat is the amount of solutions) were recorded for each patient. Postoperative blood atrial pressure in the two groups (data not shown). Temporary inotropic and/or vasopressor support was needed for weaning loss was measured and recorded by observing the volume of drainage into volumetric chest tube drains until their removal from CPB in 14 patients in the saline group and in 15 in the aprotinin group; intra-aortic counterpulsation was required (approximately 24-36 h).
in one patient in each group. Postoperative myocardial infarct
Statistical analysis
was diagnosed in two patients in the saline and in one patient in the aprotinin group. Duration of mechanical ventilation, Sample size calculation was based on estimates of urinary stay in the ICU and time to discharge did not differ between excretion of cGMP and prostanoids, determined in a prelimingroups. ary experiment. The calculations indicated that 28 patients
In the aprotinin group, postoperative blood loss (775 (314) were needed in each group to show a difference of ജ1.2 SD ml) and blood transfusion requirements (1.4 (0.7) u) were (powerϭ90%, significanceϭ5%).
significantly less than in the control group (1185 (403) ml All data are expressed as mean (SD or range); differences and 2.6 (1.4) u, respectively). were considered significant if PϽ0.05. Two-way analysis of variance with Dunnett's test was used for within-group Perioperative renal function comparisons with respect to baseline. Chi-square analysis with Yates' correction was used to compare percentages of In the control group, urinary kallikrein excretion did not patients. Simple linear correlation (Pearson) or regression change from before to after bypass (2.52 (1.94) and 3.14 analysis was used to evaluate the relationship between vari-(2.18) kat litre -1 , respectively) whereas aprotinin treatment ables. For ANP, cGMP and prostanoid analysis, data were was associated with significant lower urinary kallikrein excrelog transformed and the concentration equal to the sensitivity tion (0.24 (0.22) and 0.31 (0.30) kat litre -1 , respectively). of the assay was assigned the value of the statistical limit of Renal function did not differ between groups at any time significance.
( Table 2) . CPB was associated with significant increases in urinary flow, C Osm and fractional excretion of sodium and potassium; all of these variables were still significantly
Results
increased shortly after weaning from CPB and had recovered
Patient characteristics and outcome
to preoperative values by day 5 after operation. During CPB, C PAH increased in the control and aprotinin groups (ϩ54% We studied 57 patients (29 in the control group and 28 in the and ϩ48%, respectively). C creat and C IN did not change signiaprotinin group); one patient in each group was subsequently ficantly throughout the study and were correlated with each excluded because of bleeding which required re-operation.
other (rϭ0.72, PϽ0.05). Another patient in the aprotinin group had a massive myocardial infarct and died shortly after surgery.
Plasma ANP, plasma and urinary cGMP
Patient characteristics, preoperative treatment and surgical data did not differ between groups (Table 1 ). There were There were no differences between groups in plasma concentrations of ANP or plasma and urinary values of cGMP. In all similar changes in mean arterial pressure, heart rate and right patients, plasma ANP decreased during bypass and increased Discussion after weaning from bypass (ϩ71% in the control group and As acute renal failure is related to mortality in cardiac surgery, ϩ93% in the aprotinin group), compared with preoperative clinicians should be aware of the potential renal damage from baseline values (Fig. 1 ). There was a significant correlation drugs. In this regard, we found that in patients with good between plasma ANP and plasma cGMP (rϭ0.52 in controls renal function, aprotinin treatment (with a mean dose of 4.1 and rϭ0.62 in the aprotinin group) and between plasma ANP mkiu) did not affect renal function during cardiac surgery and right atrial pressure (rϭ0.41 in controls and rϭ0.52 in with moderate hypothermic CPB. CPB impaired renal solute the aprotinin group). reabsorption, regardless of aprotinin pretreatment, and was Changes in plasma cGMP mimicked those of plasma ANP, associated with renal release of vasodilatory mediators (nitric although they did not reach statistical significance. Urinary oxide and prostacyclin), indicated by urinary excretion of excretion of cGMP increased significantly during and after their respective metabolites (cGMP and 6-keto-PGF 1α ). bypass and was positively correlated with C Osm (rϭ0.79 and 0.86 in the control and aprotinin groups, respectively).
Aprotinin dose regimen Plasma and urinary TxB 2 and 6-keto-PGF 1α
Different doses of aprotinin have different effects on coagulation, fibrinolysis and the inflammatory cascade. 12 Patients in the aprotinin group did not differ from those Compared with the standard high-dose aprotinin treatment in the control group in plasma concentrations and urinary (2 mkiu before bypass, 2 mkiu in the pump prime and an excretion of 6-keto-PGF 1α and TxB 2 and their respective infusion of 0.5 mkiu h -1 ), a smaller dose (using only 2 ratios. After the start of bypass, the ratio of plasma concentramkiu in the pump prime) can also reduce postoperative tions of 6-keto-PGF 1α to TxB 2 increased significantly because blood loss. 13 14 At plasma concentrations greater than 50 of an increase in 6-keto-PGF 1α , while TxB 2 remained kiu ml -1 , plasmin is inhibited, whereas 200 kiu ml -1 is unchanged (Fig. 2) .
needed to suppress plasma kallikrein. According to a Urinary excretion of TxB 2 and 6-keto-PGF 1α increased pharmacokinetic model proposed by Levy, Bailey and significantly during and after CPB. The ratio of 6-keto-PGF 1α Salmenpera, 15 target plasma concentrations of 200 kiu ml -1 to TxB 2 was increased because of greater urinary excretion can be achieved with a bolus of aprotinin 2 mkiu in the of 6-keto-PGF 1α than TxB 2 (Fig. 3) . In the two groups, C Osm pre-bypass period, 1 mkiu added to the CPB circuit and an was directly related to urinary excretion of 6-keto-PGF 1α (rϭ infusion of 0.5 mkiu h -1 . We used a slightly higher dose 0.63 and 0.69 in the control and aprotinin groups) and to the regimen (1 mkiu instead of 0.5 mkiu in the pump prime) ratio of 6-keto-PGF 1α to TxB 2 (rϭ0.52 and 0.54 in the control and aprotinin groups, respectively).
that gave a 34% reduction in postoperative blood loss and the ratio 6-keto-PGF 1α to TxB 2 in the two groups of patients undergoing urinary cyclic guanidine monophosphate (cGMP) in the two groups of cardiac surgery. Data are mean (SD).*Significant difference from baseline patients undergoing cardiac surgery. Data are mean (SD).*Significant (preoperative) (PϽ0.05). difference from baseline (preoperative) (PϽ0.05). No differences between groups. messenger cGMP. 18 Although we observed no change in plasma concentrations of ANP after infusion of aprotinin, reduced allogenic blood transfusion. As the affinity of we cannot exclude the possibility that inhibition of ANP aprotinin for renal tissue is greater than for plasma kallikrein, metabolism 10 was compensated for by a reduction in ANP it was not surprising to observe 90% suppression of urinary synthesis in atrial tissues. excretion of kallikrein.
Increased plasma and urinary ratios of 6-keto-PGF 1α to TxB 2 during CPB indicate that the balance of prostanoid
Aprotinin and ANP-cGMP and prostanoids
synthesis was shifted towards prostacyclin-induced vasodilpathways atation which could prevent the vasoconstrictive and thrombogenic effect of TxA 2 . Plasma concentrations of ANP and systemic and renal formation of TxA 2 , prostacyclin and nitric oxide were
In clinically relevant concentrations (50-500 mkiu), aprotinin had no effect on endothelial and tubular release of similar in the two groups. The relationships we found between plasma concentrations of ANP, plasma cGMP and prostacyclin 19 and therefore it did not influence perioperative plasma and urinary 6-keto-PGF 1α concentrations. right atrial pressure confirmed that, even during operation, atrial release of ANP is triggered by changes in cardiac
In contrast with previous reports showing reduced platelet release of TxA 2 in aprotinin-treated patients, we found filling pressure 16 17 and that plasma ANP concentrations largely determine circulating concentrations of its second similar plasma TxB 2 concentrations in the two groups. 20 21 characterized by impaired solute reabsorption, a brisk osmolar diuresis and increases in fractional excretion of sodium and potassium. Importantly, we observed a close relationship between osmolar diuresis and renal production of vasodilatory mediators during cardiac surgery. Urinary excretion of 6-keto-PGF 1α , TxB 2 and cGMP reflect renal synthesis of prostacyclin, TxA 2 and nitric oxide. 24 During hypothermic CPB, enhanced salt and water excretion may result from several mechanisms: first, prostanoids antagonize the in vivo effect of antidiuretic hormone and inhibit Na ϩ /Cl -reabsorption in the proximal and distal nephron and in the loop of Henle 25 ; second, in the papilla, PGI 2 -and NO-mediated medullary vasodilatation prevents the papillary Na ϩ /Clcountercurrent exchange by disrupting the hyperosmolar gradient 26 ; third, tubular solute reabsorption is impaired by reduced activity of Na ϩ /Cl -membrane pumps during hypothermia.
Aprotinin, cardiac surgery and renal dysfunction
The use of aprotinin in clinical practice has not been associated with an increased incidence of postoperative renal failure. [27] [28] [29] In patients undergoing deep hypothermic arrest, the benefits and safety of aprotinin need further study. 30 31 In a large multicentre study, 32 the need for haemodialysis or filtration was strongly related to poor preoperative renal function, vascular disease and heart failure, type of surgery and use of intra-aortic balloon pump.
Despite inhibition of the kallikrein-kinin pathways, aprotinin pretreatment did not influence prostaglandin synthesis, glomerular filtration, renal plasma flow or tubular transport mechanisms. This suggests that the kallikrein-kinin pathways play a minor role in renal homeostasis and that other factors (e.g. renin-angiotensin system) may stimulate the synthesis of prostanoids during cardiac surgery. Interestingly, in animal models of sepsis 33 and in humans with In contrast with our data and other studies, 27 28 35 some difference from baseline (preoperative) (PϽ0.05).
investigators reported mild and transient postoperative increases in serum creatinine concentrations, C Osm and In fact, maximal release of PGI 2 occurs shortly after the FE Naϩ in patients given aprotinin. 6 20 However, these studies start of CPB whereas peak plasma TxB 2 concentrations were not designed to assess renal outcome; changes in renal occur during rewarming at the end of CPB. 22 As we function were not great and no details were available on measured prostaglandins approximately 20 min after the perioperative haemodynamic control and the use of fluids, start of CPB and before chest closure, we were unable to diuretics and mannitol. For instance, in the study of Blauhut document the suppressive effect of aprotinin on plasma and colleagues, 20 increased C Osm was more likely related TxB 2 .
to significant higher arterial pressure values which resulted in pressure-induced natriuresis in aprotinin-treated patients.
Renal dysfunction and CPB
In summary, we found no evidence that in patients undergoing cardiac surgery with hypothermic bypass, a As reported elsewhere, 23 we found no reduction in glomerular filtration rate and renal plasma flow during hypothermic high dose of aprotinin had an adverse effect on renal function or influenced its autoregulatory control mechanisms extracorporeal bypass as long as mean arterial pressure and pump flow were maintained within the physiological range involving prostanoids and ANP. Nevertheless, until more data are available, a lower dose is still recommended in of autoregulation. In the two groups, increased C PAH overestimated renal plasma flow because tubular extraction patients who have diabetes mellitus or renal insufficiency, and in those receiving chronic treatment with angiotensinof PAH was reduced. Transient tubular dysfunction was
